Retracted: Effect of blonanserin on cognitive function in antipsychotic‐naïve first‐episode schizophrenia

  title={Retracted: Effect of blonanserin on cognitive function in antipsychotic‐na{\"i}ve first‐episode schizophrenia},
  author={Tomomi Tenjin and Seiya Miyamoto and Nobumi Miyake and Shin Ogino and Rei Kitajima and Kazuaki Ojima and Jun Arai and Haruki Teramoto and Sachiko Tsukahara and Yukie Ito and Masanori Tadokoro and Kiriko Anai and Yasuyuki Funamoto and Yasuhiro Kaneda and Tomiki Sumiyoshi and Noboru Yamaguchi},
  journal={Human Psychopharmacology: Clinical and Experimental},
The purpose of this study was to evaluate the effects of blonanserin, a novel antipsychotic, on cognitive function in first‐episode schizophrenia. 

Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes

  • S. Stahl
  • Psychology, Biology
    CNS Spectrums
  • 2017
Drugs for psychosis and mood that bind dopamine D2 receptors can be classified not only by whether they also block serotonin 2A receptors, but by whether they also bind D3 or D1 receptors.

Efficacy and safety of blonanserin versus other antipsychotics: a review

Evaluated efficacy and tolerability of blonanserin in patients with schizophrenia and delirium is found to be effective and well tolerated.

Profile of blonanserin for the treatment of schizophrenia

Results suggest that blonanserin may be a promising candidate for a first-line antipsychotic for acute and maintenance therapy for schizophrenia.

Newer antipsychotics and upcoming molecules for schizophrenia

Although regulatory bodies have approved only a handful of antipsychotic drugs in recent years, the wide spectrum of targets that are being explored could eventually bring out antipsychotics with improved efficacy and acceptability, as well as the potential to revolutionize psychiatric practice.

Blonanserin Ameliorates Phencyclidine-Induced Visual-Recognition Memory Deficits: the Complex Mechanism of Blonanserin Action Involving D3-5-HT2A and D1-NMDA Receptors in the mPFC

The results suggest that the ameliorating effect of blonanserin on PCP-induced cognitive impairment is associated with indirect functional stimulation of the dopamine-D1-PKA-NMDA receptor pathway following augmentation of dopaminergic neurotransmission due to inhibition of both dopamine- D3 and serotonin 5-HT2A receptors in the mPFC.



Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia

Aims:  The purpose of the present study was to examine the extent of the effects of psychopathological symptoms and cognitive function on quality of life (QOL) in patients with chronic schizophrenia.

Neuropsychologic deficits in schizophrenia : Relation to social function and effect of antipsychotic drug treatment

Clozapine, which has superior antipsychotic effects compared to typical neuroleptic drugs, has been reported to improve executive function, verbal fluency, attention, and recall memory in two of three studies.

Effect of second-generation antipsychotics on cognition: current issues and future challenges

Drug discovery may benefit from greater utilization of translational neurocognitive biomarkers to bridge preclinical and clinical proof-of-concept studies, to optimize assay sensitivity, enhance cost efficiency, and speed progress in drug development.

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

Olanzapine has a beneficial effect on neurocognitive function in patients with a first episode of psychosis, however, in a comparison of the effects of olanzapine and low doses of haloperidol, the difference in benefit is small.

Effects of Low-Dose Risperidone and Low-Dose Zuclopenthixol on Cognitive Functions in First-Episode Drug-Naïve Schizophrenic Patients

This study does not support efficacy of either risperidone or zuclopenthixol on cognitive functions in drug-naïve schizophrenia patients after 3 months of medication, because neither could be distinguished from retest effects of the healthy control group.

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

The cognitive improvements observed in the trial were consistent in magnitude with practice effects observed in healthy controls, suggesting that some of the improvements in cognition in the first-episode schizophrenia group may have been due to practice effects (ie, exposure, familiarity, and/or procedural learning).

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

The extent to which 15 studies on the effect of atypical antipsychotics met newly established standards for research design in studies of treatment effects on cognitive function in schizophrenia is determined and directions for the development of new therapeutic strategies are suggested.

Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.